Is the Pharma Industry Facing Pharmageddon? Pfizer Inc. (PFE) and More

Page 1 of 2

The pharmaceuticals industry has always been one of the riskiest in the market. Companies operating in the pharma industry are required to invest heavily in research and development on drugs whose outcome is highly unpredictable. Companies like Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), and Johnson & Johnson (NYSE:JNJ) among others, have toiled this red flagged industry for years. Note that, despite the risks associated with investing in the industry, the potential upside is always enormous. No wonder, they say, “the higher the risk, the higher, the return.” But this is not always the case.

Pfizer Inc. (NYSE:PFE)What’s in this industry anyway?

The Pharma industry holds one of the biggest potential upsides across all sectors. Perhaps only Technology and Energy can compete on equal footing. Nonetheless, the attractiveness of this industry is yet the biggest peril for investors. Sounds like a paradox? Well, here is the deal. Some investors view the industry as next to gambling. Indeed, if a company, say Johnson & Johnson (NYSE:JNJ), manages to get things right and gets approval from Food and Drug Administration (FDA) to proceed with the licensing and the manufacture of a certain drug, then the returns are usually skewed to the right. The opposite is usually true.

A good example is the anticipated launch of three drugs by Pfizer, which have fuelled the demand for its stock, pushing it to a new five and a half-year high of $27.65, on February 1. The company received approval from FDA for its Rheumatoid Arthritis treatment available in pill form in November 2012, although it is yet to receive the marketing materials approval. It also received two more approvals in January.

Elsewhere, Johnson & Johnson is expected to improve significantly during the current campaign following the approval by FDA for a drug that is expected to treat a form of resistant tuberculosis that is uncommon in the U.S., but growing globally. On the other hand, Mylan Inc. (NASDAQ:MYL) is said to have received final approval from FDA for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets. The drug is a generic type of Merck’s Maxalt MLT and Maxalt tablets.

The Pharmageddon?

According to a report published by PriceWaterhouseCoopers (PWC) in November 2012, the pharma industry is expected to more than double its current value to the tune of $1.3 trillion by the year 2020. However, for large pharmas to romp in tandem with the industry, they are expected to change their game by diversifying their services and products, as the quandary of costs balloons to levels that could threaten disintegration. Indeed, this is already very evident with the rate of spin-offs already witnessed in the industry.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!